our follow-up ( 24 months or more ) data of 41 patients with clinical stage i disease , and of 21 patients with clinical stage iii or iv disease show that the receptor-poor tumors tend to behave more aggressively than receptor-rich malignancies in relation to patient survival .
C0012634
disease
C0027651
tumors